Fresenius Kabi intros generic Dotarem

Fresenius Kabi is offering gadoterate meglumine injection, a generic of Guerbet’s contrast agent Dotarem.

This is the second contrast agent introduced by Fresenius Kabi in the United States this year. The company previously introduced Iodixanol Injection in July during a nationwide shortage.

[Read more: Fresenius Kabi intros generic Tepadina]

Contrast agents, a new category of healthcare products for Fresenius Kabi, are used by radiologists to enhance the visibility of internal structures in imaging procedures such as MRI or CT scans.

“Fresenius Kabi is pleased to expand our contrast agent portfolio and our support for the radiology community with the launch of gadoterate meglumine injection,” said John Ducker, president and CEO of Fresenius Kabi USA. “Contrast agents are vital to patient diagnosis, and the addition of Fresenius Kabi gadoterate meglumine will provide hospitals and clinics across the United States with more high-quality choices to support patient care.”

Gadoterate meglumine injection is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging in the brain (intracranial), spine, and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood-brain barrier and/or abnormal vascularity.

[Read more: Fresenius Kabi intros generic Foscovir] 

Fresenius Kabi said the product is available in 5-, 10-, 15- and 20-ml single-dose vials.